Use fundamental data analysis to double-check all available reported financial drivers of BioShares Biotechnology to find out if markets are presently mispricing the etf. We found ten available fundamental indicators for BioShares Biotechnology Products which can be compared to its rivals. Please makes use of BioShares Biotechnology Price to Book and One Year Return to make a decision on weather BioShares Biotechnology is priced fairly. Use BioShares Biotechnology to protect against small markets fluctuations. The etf experiences somewhat bearish sentiment, but market may correct it shortly. Check odds of BioShares Biotechnology to be traded at $39.43 in 30 days
BioShares Biotechnology Company SummaryBioShares Biotechnology competes with Health Care, iShares Nasdaq, Vanguard Health, SPDR SP, and ISHARE DJ. The investment seeks investment results that correspond, before fees and expenses, to the price and yield performance of the LifeSci Biotechnology Products Index. Under normal market conditions, the fund will invest not less than 80 percent of its assets in component securities of the index. The index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with at least one drug therapy approved by the U.S. Food and Drug Administration for marketing. The fund is non-diversified.
BioShares Biotechnology Net Asset vs Price to Sales
BioShares Biotechnology Products is rated below average in net asset as compared to similar ETFs. It is second largest ETF in price to sales as compared to similar ETFs . The ratio of Net Asset to Price to Sales for BioShares Biotechnology Products is about 6,871,429